Analysis of the diversity of the HIV-1 pol gene and drug resistance associated changes among drug-naïve patients in Burkina Faso

Journal of Medical Virology

Volumn 81, Issue 10, 2009, Pages 1691-1701

  Tebit, Denis M ^a,d   Sangaré, Lassana ^b   Tiba, Fabrice ^a   Saydou, Yameogo ^b   Makamtse, Aline ^b   Somlare, Hermann ^b   Bado, Guillaume ^b   Kouldiaty, Boris G ^b   Zabsonre, Inoussa ^c   Yameogo, Sibiri L ^c   Sathiandee, Kanokporn ^a   Drabo, Joseph Y ^c   Kräusslich, Hans Georg ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b CENTRE HOSPITALIER UNIVERSITAIRE YALGADO OUÉDRAOGO   (Burkina Faso)

^c Yalgado Ouedraogo Teaching Hospital   (Burkina Faso)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Burkina Faso; Drug na ve and resistance; HIV; Pol diversity

Indexed keywords

EPITOPE; PROTEINASE; RNA DIRECTED DNA POLYMERASE;

ADOLESCENT; ADULT; ARTICLE; BOOTSTRAPPING; BURKINA FASO; CHILD; CLINICAL STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MUTATION; PREVALENCE; SCHOOL CHILD; SEQUENCE ANALYSIS; STRUCTURAL GENE;

ADOLESCENT; ADULT; BURKINA FASO; CHILD; CLUSTER ANALYSIS; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PHYLOGENY; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RECOMBINATION, GENETIC; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 69949165748     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21600     Document Type: Article

References (43)

1. Adjé-Touré C, Celestin B, Hanson D, Roels TH, Hertogs K, Larder B, Diomande F, Peeters M, Eholié S, Lackritz E, Chorba T, Nkengasong JN. 2003. Prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS-Drug Access Initiative in Abidjan, Côte d'Ivoire. AIDS 17:S23-S29. (Pubitemid 36951666)
2. Clavel F, Hance AJ. 2004. HIV drug resistance. N Engl J Med 350:1023-1035.
3. Derache A, Maiga AI, Traore O, Akonde A, Cisse M, Jarrousse B, Koita V, Diarra B, Carcelain G, Barin F, Pizzocolo C, Pizarro L, Katlama C, Calvez V, Marcelin AG. 2008. Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006. J Antimicrob Chemother 62:456-463.
4. Descamps D, Apetrei C, Collin G, Damond F, Simon F, Brun-Vézinet F. 1998. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors. AIDS 12:1109-1111. (Pubitemid 28276983)
5. Gianotti N, Galli L, Boeri E, De Bona A, Guffanti M, Danise A, Salpietro S, Lazzarin A, Castagna A. 2006. The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr 41:447-452. (Pubitemid 43756160)
6. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA, Giangrande P, Luzzi G, Morgan B, Edwards A, McMichael AJ, Rowland-Jones S. 1997. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 3:212-217. (Pubitemid 27064707)
7. Jacobs GB, Laten A, van Rensburg EJ, Bodem J, Weissbrich B, Rethwilm A, Preiser W, Engelbrecht S. 2008. Phylogenetic diversity and low level antiretroviral resistance mutations in HIV type 1 treatment-naive patients from Cape Town, South Africa. AIDS Res Hum Retroviruses 24:1009-1012.
8. Johnson JA, Li JF, Morris L, Martinson N, Gray G, McIntyre J, Heneine W. 2005. Emergence of drug resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 192:16-23. (Pubitemid 40863852)
9. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkitzkes DR, Pillay D, Schapiro JM, Richman DD. 2008. Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med 16:62-68.
10. Konings FA, Nyambi PN. 2004. V118I substitution in the reverse transcriptase gene of HIV type 1 CRF02-AG strains infecting drug-naive individuals in Cameroon. AIDS Res Hum Retroviruses 20:673-678.
11. Lall M, Gupta RM, Sen S, Kapila K, Tripathy SP, Paranjape RS. 2008. Profile of primary resistance in human immunodeficiency virus type 1 (HIV-1)-infected treatment-naive individuals from Western India. AIDS Res Hum Retroviruses 24:987-990.
12. Lloyd B, O'Connell RJ, Michael NL, Aviles R, Palou E, Hernandez R, Cooley J, Jagodzinski LL. 2008. Prevalence of resistance mutations in HIV-1-Infected Hondurans at the beginning of the National Antiretroviral Therapy Program. AIDS Res Hum Retroviruses 24:529-535. (Pubitemid 351571035)
13. Loemba H, Brenner B, Parniak MA, Ma'ayan S, Spira B, Moisi D, Oliveira M, Detorio M, Essex M, Wainberg MA. 2002. Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance. Antivir Res 56:129-142.
14. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, Ingersoll R, Sheppard HW, Ray SC. 1999. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 73:152-160. (Pubitemid 28565356)
15. Manigart O, Courgnaud V, Sanou O, Valea D, Nagot N, Meda N, Delaporte E, Peeters M, Van de Perre P. 2004. HIV-1 superinfections in a cohort of commercial sex workers in Burkina Faso as assessed by an autologous heteroduplex mobility procedure. AIDS 18:1645-1651. (Pubitemid 39095781)
16. Mason RD, Bowmer MI, Howley CM, Gallant M, Myers JC, Grant MD. 2004. Antiretroviral drug resistance mutations sustain or enhance CTL recognition of common HIV-1 Pol epitopes. J Immunol 172:7212-7219. (Pubitemid 38669167)
17. Meloni ST, Sankalé JL, Hamel DJ, Eisen G, Guéye-Ndiaye A, Mboup S, Kanki PJ. 2004. Molecular epidemiology of human immunodeficiency virus type 1 sub-subtype A3 in Senegal from 1988 to 2001. J Virol 78:12455-12461. (Pubitemid 39462002)
18. Modiano D, Luoni G, Petrarca V, Sodiomon Sirima B, De Luca M, Simporé J, Coluzzi M, Bodmer JG, Modiano G. 2001. HLA class I in three West African ethnic groups: Genetic distances from sub-Saharan and Caucasoid populations. Tissue Antigens 57:128-137. (Pubitemid 32245233)
19. Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. 2002. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296:1439-1443. (Pubitemid 34553083)
20. Nadembega WM, Giannella S, Simpore J, Ceccherini-Silberstein F, Pietra V, Bertoli A, Pignatelli S, Bellocchi MC, Nikiema JB, Cappelli G, Bere A, Colizzi V, Perno CP, Musumeci S. 2006. Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso. J Med Virol 78:1385-1391. (Pubitemid 44533865)
21. Ndembi N, Abraha A, Pilch H, Ichimura H, Mbanya D, Kaptue L, Salata R, Arts EJ. 2008. Molecular characterization of human immunodeficiency virus type 1 (HIV-1) and HIV-2 in Yaounde, Cameroon: Evidence of major drug resistance mutations in newly diagnosed patients infected with subtypes other than subtype B. J Clin Microbiol 46:177-184.
22. Novitsky V, Wester CW, DeGruttola V, Bussmann H, Gaseitsiwe S, Thomas A, Moyo S, Musonda R, Van Widenfelt E, Marlink RG, Essex M. 2007. The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa. AIDS Res Hum Retroviruses 23:868-878. (Pubitemid 47267493)
23. Oette M, Kaiser R, Däumer M, Petch R, Fätkenheuer G, Carls H, Rockstroh JK, Schmalöer D, Stechel J, Feldt T, Pfister H, Häussinger D. 2006. Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr 41:573-581. (Pubitemid 43756138)
24. Ojesina AI, Sankalé JL, Odaibo G, Langevin S, Meloni ST, Sarr AD, Olaleye D, Kanki PJ. 2006. Subtype-specific patterns in HIV Type 1 reverse transcriptase and protease in Oyo State, Nigeria: Implications for drug resistance and host response. AIDS Res Hum Retroviruses 22:770-779. (Pubitemid 44735004)
25. Ouedraogo-Traore R, Montavon C, Sanou T, Vidal N, Sangaré L, Sanou I, Soudré R, Mboup S, Delaporte E, Peeters M. 2003. CRF06-cpx is the predominant HIV-1 variant in AIDS patients from Ouagadougou, the capital city of Burkina Faso. AIDS 17:441-442. (Pubitemid 36223269)
26. Petch LA, Hoffman IF, Jere CS, Kazembe PN, Martinson FE, Chilongozi D, Fiscus SA, Cohen MS. 2005. Genotypic analysis of the protease and reverse transcriptase of HIV type 1 subtype C isolates from antiretroviral drug-naive adults in Malawi. AIDS Res Hum Retroviruses 21:799-805. (Pubitemid 41434185)
27. Samri A, Haas G, Duntze J, Bouley JM, Calvez V, Katlama C, Autran B. 2000. Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells. J Virol 74:9306-9312. (Pubitemid 30759634)
28. Seyler C, Adjé-Touré C, Messou E, Dakoury-Dogbo N, Rouet F, Gabillard D, Nolan M, Toure S, Anglaret X. 2007. Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa. AIDS 21:1157-1164. (Pubitemid 46763286)
29. Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM, Kuritzkes DR, Bennett D. 2007. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 21:215-223. (Pubitemid 46036930)
30. Shet A, Berry L, Mohri H, Mehandru S, Chung C, Kim A, Jean-Pierre P, Hogan C, Simon V, Boden D, Markowitz M. 2006. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: A decade of experience. J Acquir Immune Defic Syndr 41:439-446. (Pubitemid 43756159)
31. Tamalet C, Pasquier C, Yahi N, Colson P, Poizot-Martin I, Lepeu G, Gallais H, Massip P, Puel J, Izopet J. 2000. Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection. J Med Virol 61:181-186. (Pubitemid 30257241)
32. Tebit DM, Zekeng L, Kaptue L, Salminen M, Kräusslich HG, Herchenröder O. 2002. Genotypic and phenotypic analysis of HIV type 1 primary isolates from western Cameroon. AIDS Res Hum Retroviruses 18:39-48. (Pubitemid 34133027)
33. Tebit DM, Ganamé J, Sathiandee K, Nagabila Y, Coulibaly B, Kräusslich HG. 2006. Diversity of HIV in rural Burkina Faso. J Acquir Immune Defic Syndr 43:144-152.
34. Tebit DM, Sangaré L, Makamtse A, Yameogo S, Somlare H, Bado G, Kouldiaty BG, Sathiandee K, Tiba F, Sanou I, Ouédraogo-Traoré R, Zoungrana L, Diallo I, Drabo JY, Kräusslich HG. 2008. HIV drug resistance pattern among HAART-exposed patients with suboptimal virological response in Ouagadougou, Burkina Faso. J Acquir Immune Defic Syndr 49:17-25.
35. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. 1997. The CLUSTAL X windows interface: Flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25:4876-4882. (Pubitemid 28022245)
36. Toni TD, Recordon-Pinson P, Minga A, Ekouevi D, Bonard D, Bequet L, Huet C, Chenal H, Rouet F, Dabis F, Lafon ME, Salamon R, Masquelier B, Fleury HJ. 2003. Presence of key drug resistance mutations in isolates from untreated patients of Abidjan, Cote d'Ivoire: ANRS 1257 study. AIDS Res Hum Retroviruses 19:713-717. (Pubitemid 37047097)
37. Toni TD, Masquelier B, Minga A, Anglaret X, Danel C, Coulibaly A, Chenal H, Dabis F, Salamon R, Fleury HJ, Primo-CI ANRS 1220 Study Group. 2007. HIV-1 antiretroviral drug resistance in recently infected patients in Abidjan, Côte d'Ivoire: A 4-year survey, 2002-2006. AIDS Res Hum Retroviruses 23:1155-1160.
38. UNAIDS. 2006. AIDS Epidemic Update. http://data.unaids.org/pub/EpiReport/ 2006/04-Sub-Saharan-Africa-2006-EpiUpdate-eng.pdf.
39. Vergne L, Diagbouga S, Kouanfack C, Aghokeng A, Butel C, Laurent C, Noumssi N, Tardy M, Sawadogo A, Drabo J, Hien H, Zekeng L, Delaporte E, Peeters M. 2006. HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon. Antivir Ther 11:575-579. (Pubitemid 44277422)
40. Violin M, Velleca R, Cozzi-Lepri A, Riva C, Grossi PA, Carnevale G, Rizzardini G, Petrelli E, Perno CF, Monforte A, Balotta C, ICoNA Study Group. 2004. Prevalence of HIV-1 primary drug resistance in seroconverters of the ICoNA cohort over the period 1996-2001. J Acquir Immune Defic Syndr 36:761-764. (Pubitemid 38685973)
41. Wainberg MA. 2004. HIV-1 subtype distribution and the problem of drug resistance. AIDS 18:S63-S68. (Pubitemid 39037462)
42. Walker BD, Flexner C, Paradis TJ, Fuller TC, Hirsch MS, Schooley RT, Moss B. 1988. HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science 240:64-66. (Pubitemid 18101472)
43. Wensing AM, van de Vijver DA, Angarano G, Asjo B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kucherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stockl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CA, SPREAD Programme. 2005. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. J Infect Dis 192:958-966.